Dr. Bejar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3855 Health Sciences Dr
# MC0820
La Jolla, CA 92093Phone+1 858-534-5204Fax+1 858-246-1847
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2006 - 2011- Brigham and Women's HospitalResidency, Internal Medicine, 2004 - 2006
University of ChicagoInternship, Internal Medicine, 2003 - 2004
University of California San Diego School of MedicineClass of 2003
Certifications & Licensure
CA State Medical License 2012 - 2026
MA State Medical License 2005 - 2014
IL State Medical License 2003 - 2006- American Board of Internal Medicine Hematology
Clinical Trials
- Collection of Samples From Patients With MDS Start of enrollment: 2017 Apr 06
- Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) Start of enrollment: 2018 Jan 01
Publications & Presentations
PubMed
- Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.Himangshu Sonowal, William G Rice, Raphael Bejar, Joo-Yun Byun, Seung Hyun Jung
Cancer Research Communications. 2025-01-01 - Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic ...Fnu Aakash, Savanah D Gisriel, Amer M Zeidan, John M Bennett, Rafael Bejar
Modern Pathology. 2024-12-01 - 2 citationsData-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.Rami S Komrokji, Luca Lanino, Somedeb Ball, Jan P Bewersdorf, Monia Marchetti
The Lancet. Haematology. 2024-11-01
Abstracts/Posters
- TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic SyndromesRafael Bejar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS StudyRafael Bejar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a L...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- DNA Methylation Identifies Genetically and Prognostically Distinct Subtypes of MDS2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Hippo Kinase Inactivation Contributes to Del(20q) Malignancies and Cooperates with JAK2-V617F to Promote Myelofibrosis in Mice2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine TrialsDecember 2nd, 2024- Aptose Reports Results for the Second Quarter 2022August 2nd, 2022
- HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid LeukemiaDecember 13th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
